id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-2965-0008,FDA,FDA-2015-E-2965,"Determination of Regulatory Review Period for Purposes of Patent
Extension; OBIZUR",Notice,Determinations,2017-10-23T04:00:00Z,2017,10,2017-10-23T04:00:00Z,2017-12-23T04:59:59Z,2017-10-23T14:23:52Z,2017-22898,0,0,0900006482bf7313
FDA-2015-E-2965-0007,FDA,FDA-2015-E-2965,Letter from FDA to U.S. Patent and Trademark Office,Other,Letter(s),2017-07-07T04:00:00Z,2017,7,2017-07-07T04:00:00Z,,2017-07-07T21:22:17Z,,0,0,09000064828463e2